Jointechlabs, Inc.

Headquartered in Brandon, FL, privately-held Jointechlabs is an emerging worldwide leader in regenerative medicine.

The company enables healthcare practitioners to provide safe, cost-effective, non-surgical therapies at the point-of-care without change in infrastructure.

FDA-cleared MiniTC® is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat. Microfat’s uses include a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Additionally, in certain markets, CE-Mark-approved Mini-Stem System® extracts microfat and Stromal Vascular Fraction. Pipeline includes development of stem-cell based therapeutics with 3D Bioprinted constructs and injectable stem cell scaffolding.

Posts attributed to Jointechlabs may have been written by one or more staff members, consultants, or third parties.

More Information: https://www.jointechlabs.com.

Home Page: https://jointechlabs.com

Posts by Jointechlabs, Inc.

MiniTC Adipose System Now Faster, More Convenient, Personalized
New syringes and a choice of cannulas will make adipose processing faster and personalized to each physician’s needs.
MDSAP Quality Certification Awarded to Jointechlabs
Jointechlabs earned the MDSAP quality certification indicating compliance with ISO13485:2016 for medical device quality management.
Jointechlabs launches European expansion with new partnerships, grants, and subsidiary
European focus includes a new subsidiary in Austria, a medical research center in partnership with a prominent health center, and development and distribution agreements for Germany, Austria, Switzerland, Italy, Spain, and the Balkans.
Jointechlabs is Granted Additional Patent for Innovations Using Adipose in Regenerative Medicine Applications
Jointechlabs has just strengthened its intellectual property position with the granting of a new US patent covering systems and methods of encapsulating stem cells.
Jointechlabs’ MiniTC Training by Dr. Nathan Katz, Ph.D., and Dr. Enrico Guarino
Drs. Katz and Guarino demonstrate the operation of MiniTC.
Guided Lymphangiogenesis for the Treatment of Lymphedema: Preliminary Clinical Results
Catarina Hadamitzky, Tatiana S. Zaitseva, Nathan Katz, Claire P Edelstein, Manuel T. Escarraman, Dung Nguyen, Michael V. Paukshto Clinic of Plastic, Aesthetic and Hand Surgery, Helios Clinic, Hildesheim, Germany. Fibralign Corporation, Union City, California, USA. JointechLabs, Inc, N. Barrington, Illinois, USA. Instituto Oncológico Dr. Heriberto Pieter, Santo Domingo, Dominican Republic. Department of Plastic Surgery, Stanford […]
3D Bioprinting of Autologous Adipose Tissue for Wound Healing
Critical skin wounds are a major cost for the health sector and lead to immense suffering for the patients. One way to facilitate the healing of these wounds is through autologous adipose tissue transplants. However, the implanted tissue needs to be vascularized or it will suffer from necrosis. To combat this Stromal vascular fraction (SVF), […]
Nanofibrillar Scaffold with Plated Adipose-Derived Stem Cells, Its Use for Lymphedema Treatment in Rats, and Path for Clinical Application
Gloria Sue, Dung Nguyen, Dimitris Dionysiou, Tatiana Zaitseva, Cristhian Montenegro, Peter Tabada, Peter Deptula, Derrick Wan, Nathan Katz, Michael Paukshto, Stanley Rockson. Stanford University, Stanford, CA, US Aristotle University of Thessaloniki, Greece Fibralign Corp, Union City, CA, US Jointechlabs, San Francisco, CA, US To address the current deficit of sustainable lymphedema treatment, we investigated lymphatic […]
Combining Freshly Isolated Adipose-derived Cells With Regenogel-OSP
Nathan Katz, MSc, Ph.D., Jointechlabs, Inc., USAAvner Yayun, MD, Ph.D., Procore Biomed, Israel Procore Biomed has developed a hyaluronic-acid – plasma cross-linked hydrogel “RegenoGel” suitable for the growth and differentiation of skeletal tissue stem and progenitor cells. Jointechlabs has provided adipose-derived cell fraction obtained by the “Mini-Stem System”, which contains a range of 2-8% of […]
Short Review: Non-cultured Adipose-derived MSCs for Treatment of OA, Jointechlabs, Inc.
Treating patients with OA presents a significant challenge for physicians as no therapies to date have demonstrated efficacy in curing or even halting disease progression. Therefore, most approaches initially target pain management and factors that may be exacerbating stress on the joint. https://dx.doi.org/10.2147%2FSCCAA.S68073 – Mayo Clinic, MN Corticosteroid toxicity for chondrocytes has been long reported, both […]